{"id":"W6921037962","doi":"10.6084/m9.figshare.23505264","title":"Additional file 1 of XENERA-1: a randomised double-blind Phase II trial of xentuzumab in combination with everolimus and exemestane versus everolimus and exemestane in patients with hormone receptor-positive/HER2-negative metastatic breast cancer and non-visceral disease","year":2023,"lang":"en","type":"article","venue":"Open MIND","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"ca_institutions":"Boehringer Ingelheim (Canada); Centre hospitalier universitaire de Québec","funders":"","keywords":"Exemestane; Everolimus; Metastatic breast cancer; Breast cancer; Phases of clinical research; Placebo; Clinical trial","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.002975986,0.001324801,0.001893723,0.0007338739,0.0006838881,0.001146434,0.001326811,0.001405646,0.8384896],"category_scores_gemma":[0.02056707,0.0007795399,0.001125583,0.001327369,0.0003463782,0.001059085,0.0005559519,0.001279698,0.06224516],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001074523,"about_ca_system_score_gemma":0.002174751,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001783789,"about_ca_topic_score_gemma":0.004172285,"domain_scores_codex":[0.9990338,0.000397147,0.0001570559,0.0001573778,0.0001349495,0.0001196556],"domain_scores_gemma":[0.9832565,0.01227726,0.001880105,0.0007321156,0.00118823,0.0006658437],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"not_applicable","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.03500475,0.001164676,0.001163813,0.01839925,0.0005595024,0.000127709,0.00006630384,0.001244551,0.0004715888,0.002340753,0.9013454,0.03811171],"study_design_scores_gemma":[0.4600782,0.008371575,0.01774485,0.005331819,0.001789878,0.0006211064,0.000100449,0.002692749,0.001594827,0.01430351,0.4871987,0.0001723138],"study_design_candidate":"randomized_trial","study_design_consensus":null,"genre_codex":"dataset","genre_gemma":"empirical","genre_scores_codex":[0.001358067,0.0003129242,0.0008825065,0.000671879,0.0001640762,0.003931831,0.9872241,0.0005595893,0.004895024],"genre_scores_gemma":[0.06839785,0.001940053,0.01912459,0.00491424,0.001014454,0.08591985,0.7555018,0.001109183,0.06207804],"genre_candidate":"empirical","genre_consensus":null,"teacher_disagreement_score":0.8384896,"threshold_uncertainty_score":0.230375,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.04055995530451263,"score_gpt":0.3517373842879856,"score_spread":0.3111774289834729,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}